WHO Sounds Warning Over Critical Lack of Weight-Loss Jabs
Less than 10% of individuals that would benefit from weight-loss injections like Wegovy are able to get them, states the global health agency as it publishes its first guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to this class of drugs.
Per projections, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidance acknowledges that excess weight is a long-term condition that can be treated with comprehensive and ongoing care," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant barriers to broad access to the jabs that can help people shift substantial weight, explains the agency.
GLP-1 Therapy Shortage
Even in the present most optimistic scenario, the supply of such drugs would only suffice for about 100 million people – less than 10% of eligible patients, according to the WHO.
The advice urges nations and manufacturers to expand access, via strategies such as voluntary licensing.
Exclusive production rights on the active ingredient – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Obesity Drugs Function
The injections imitate a natural hormone to slow digestion, reduce hunger and enhance feelings of fullness so people eat less.
People commonly see weight reduction in the initial weeks of commencing the regular doses.
Evidence points to patients may see weight return a year later of discontinuing the medication, because their normal food cravings come back.
To be above a healthy weight increases your likelihood for contracting health problems, such as diabetes, heart disease, brain attack, and certain cancers.
Excess weight affects people in every country and was associated with 3.7 million deaths worldwide in 2024, according to the health agency.
